Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis

Yuki Kagoya; Yasuhito Nannya; Mineo Kurokawa

doi:10.1016/j.leukres.2012.04.001

Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis

Yuki Kagoya, Yasuhito Nannya, Mineo Kurokawa

Research output: Contribution to journal › Article › peer-review

Abstract

We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma. Overall, 6 trials including 2786 patients were identified. Patients treated with thalidomide maintenance had marginally better overall survival (hazard ratio HR 0.83, P= 0.07). The improvement was especially prominent in a subgroup of studies using corticosteroids with thalidomide (HR 0.70, P= 0.02). Thalidomide improved progression-free survival (HR 0.65, P< 0.01), but had more frequent venous thrombosis (risk difference 0.024, P< 0.05) and peripheral neuropathy (risk difference 0.072, P< 0.01). These results suggest that thalidomide maintenance with corticosteroids is effective in prolonging survival for multiple myeloma.

Original language	English
Pages (from-to)	1016-1021
Number of pages	6
Journal	Leukemia Research
Volume	36
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2012.04.001
Publication status	Published - 2012 Aug
Externally published	Yes

Keywords

Corticosteroid
Maintenance therapy
Meta-analysis
Multiple myeloma
Randomized controlled trials
Thalidomide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2012.04.001

Cite this

@article{22f3c6d94be74fc39b9187f0aed28c06,

title = "Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis",

abstract = "We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma. Overall, 6 trials including 2786 patients were identified. Patients treated with thalidomide maintenance had marginally better overall survival (hazard ratio HR 0.83, P= 0.07). The improvement was especially prominent in a subgroup of studies using corticosteroids with thalidomide (HR 0.70, P= 0.02). Thalidomide improved progression-free survival (HR 0.65, P< 0.01), but had more frequent venous thrombosis (risk difference 0.024, P< 0.05) and peripheral neuropathy (risk difference 0.072, P< 0.01). These results suggest that thalidomide maintenance with corticosteroids is effective in prolonging survival for multiple myeloma.",

keywords = "Corticosteroid, Maintenance therapy, Meta-analysis, Multiple myeloma, Randomized controlled trials, Thalidomide",

author = "Yuki Kagoya and Yasuhito Nannya and Mineo Kurokawa",

year = "2012",

month = aug,

doi = "10.1016/j.leukres.2012.04.001",

language = "English",

volume = "36",

pages = "1016--1021",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Thalidomide maintenance therapy for patients with multiple myeloma

T2 - Meta-analysis

AU - Kagoya, Yuki

AU - Nannya, Yasuhito

AU - Kurokawa, Mineo

PY - 2012/8

Y1 - 2012/8

N2 - We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma. Overall, 6 trials including 2786 patients were identified. Patients treated with thalidomide maintenance had marginally better overall survival (hazard ratio HR 0.83, P= 0.07). The improvement was especially prominent in a subgroup of studies using corticosteroids with thalidomide (HR 0.70, P= 0.02). Thalidomide improved progression-free survival (HR 0.65, P< 0.01), but had more frequent venous thrombosis (risk difference 0.024, P< 0.05) and peripheral neuropathy (risk difference 0.072, P< 0.01). These results suggest that thalidomide maintenance with corticosteroids is effective in prolonging survival for multiple myeloma.

AB - We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma. Overall, 6 trials including 2786 patients were identified. Patients treated with thalidomide maintenance had marginally better overall survival (hazard ratio HR 0.83, P= 0.07). The improvement was especially prominent in a subgroup of studies using corticosteroids with thalidomide (HR 0.70, P= 0.02). Thalidomide improved progression-free survival (HR 0.65, P< 0.01), but had more frequent venous thrombosis (risk difference 0.024, P< 0.05) and peripheral neuropathy (risk difference 0.072, P< 0.01). These results suggest that thalidomide maintenance with corticosteroids is effective in prolonging survival for multiple myeloma.

KW - Corticosteroid

KW - Maintenance therapy

KW - Meta-analysis

KW - Multiple myeloma

KW - Randomized controlled trials

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84862512787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862512787&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.001

DO - 10.1016/j.leukres.2012.04.001

M3 - Article

C2 - 22579366

AN - SCOPUS:84862512787

SN - 0145-2126

VL - 36

SP - 1016

EP - 1021

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this